Generic Name and Formulations:
Sulfadiazine 500mg; tabs.
Indications for Sulfadiazine:
Susceptible infections including chancroid, trachoma, inclusion conjunctivitis, nocardiosis, UTI (secondary therapy), toxoplasmosis encephalitis, meningococcal meningitis, acute otitis media, rheumatic fever.
Initially 2–4g. Maintenance: 2–4g divided into 3–6 doses every 24 hours.
<2 months: see Contraindications. ≥2months: Initially ½ the 24-hour dose. Maintenance: 150mg/kg divided into 4–6 doses every 24 hours, max 6g/24hrs. Rheumatic fever prophylaxis: <30kg: 500mg every 24 hours; >30kg: 1g every 24 hours.
Infants <2 months of age (except as adjunctive therapy with pyrimethamine in the treatment of congenital toxoplasmosis). Pregnancy at term. Nursing mothers.
Do not use to treat group A betahemolytic streptococcal infections. Renal or hepatic impairment. Bronchial asthma. Severe allergy. G6PD deficiency. Maintain adequate hydration. Obtain CBCs and urinalyses frequently during therapy. Pregnancy (Cat.C).
May be potentiated by indomethacin, probenecid, salicylates. May potentiate oral anticoagulants, methotrexate, sulfonylureas, thiazide diuretics, uricosuric agents.
Blood dyscrasias, allergic reactions, GI upset, hepatitis, pancreatitis, stomatitis, headache, peripheral neuritis, depression, convulsions, ataxia, hallucinations, tinnitus, vertigo, insomnia, crystalluria, stone formation, toxic nephrosis, oliguria, anuria; rare: goiter production, diuresis, hypoglycemia.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline